Bambusa IPO: how the business makes money

Bambusa Therapeutics spends investors' money testing antibody drugs for immune and inflammatory diseases; it has no products on sale and no revenue.

• 01Nobody pays Bambusa for a product yet. Revenue was $0 in every period in its prospectus. Preferred stock sales of $136.1 million and the $168.9 million IPO priced Oct 29, 2026 fund it.
• 02In FY2025 it spent $38.1 million on research and development, and its net loss was $41.1 million.

New shares sold by the company

$169M · 10.56 million shares

Listed on

Nasdaq

Ticker

BBTX

Lock-up on existing holders

180 days

Listing date (as stated)

Oct 30, 2026

• 01New shares: Bambusa sold every share, so the money goes to the company. The prospectus lists no selling stockholders.
• 02After an $11.8 million underwriting discount and about $4.6 million of other costs, the prospectus puts the money Bambusa keeps at about $152.4 million.
• 03The S-1/A of Oct 26, 2026 gave a range of $15.00 to $17.00 and 9,375,000 shares. The final terms were 10,555,555 shares at $16.00, the range's midpoint.
• 04Underwriters can buy up to 1,583,333 more shares from Bambusa for 30 days. No filing read through Nov 5, 2026 says whether they did.
• 05The shares first traded on Nasdaq as BBTX on Oct 30, 2026. Nasdaq's table shows a $14.88 open and a $14.99 close that day, and a $16.07 close on Nov 4, 2026.
• 06That $14.88 open was 7.0% below the $16.00 offering price (Cityfort calculation from Nasdaq's Oct 30, 2026 opening price and 424B4 filed Oct 30, 2026).
• 07An 8-K filed Nov 3, 2026 reports the IPO's completion on Nov 2, 2026.

Bambusa, its officers and directors, and substantially all holders agreed not to sell for 180 days after Oct 29, 2026. BofA Securities and Evercore can consent to an early release.

Underwriters

4 named in the S-1 (lead: BofA Securities, Evercore Group, UBS Securities, Cantor Fitzgerald)

Controlled company

The prospectus does not say Bambusa will be a controlled company under Nasdaq rules.

Directed share programme

Up to 3.5% of the offered shares were reserved for directors, officers, employees, distributors, dealers, business associates and related persons, per the prospectus.

Lead underwriters

BofA Securities, Evercore Group, UBS Securities, Cantor Fitzgerald

Transfer agent

Fidelity Stock Transfer Solutions LLC

Source: Bambusa Therapeutics, Inc. final prospectus filed under Rule 424(b)(4), dated Oct 29, 2026 (Registration No. 333-299405); Nasdaq historical quotes for BBTX, Oct 30 to Nov 4, 2026 (open, high, low, close, volume), read Nov 5, 2026; Bambusa Therapeutics, Inc. Form S-1/A (Amendment No. 1), filed Oct 26, 2026: states the $15.00-$17.00 price range and 9,375,000 shares and 3 more

Learn: How to read an S-1: Anthropic's IPO registration statement · IPO lock-up agreements: what they are and when they end

• Continued development of BBT001, including a planned Phase 2b trial in atopic dermatitisAbout $90.0 million, as stated in the prospectus.$90M
• Continued development of BBT002, including an expected Phase 2b trial in one respiratory diseaseAbout $40.0 million, as stated in the prospectus.$40M
• Research on BBT003 and BBT004, equipment spending, working capital, general corporate purposes and public-company costsThe prospectus gives no amount for this remainder. It says a portion may go on licenses or acquisitions, with none committed.Amount not fixed

The company says this money plus existing cash funds operating expenses and equipment spending into late 2028, based on assumptions that may prove wrong. It says that is not enough to take all its drug candidates through regulatory approval. It also says it will need substantial additional capital.

Only the shares the company sells raise money for it; money from shares sold by existing stockholders goes to them.

Learn: IPO lock-up agreements: what they are and when they end

• BBT001 (lead candidate)

  Aimed at IL-4Rα and IL-31, for atopic dermatitis (a form of eczema) and chronic spontaneous urticaria (recurring hives). In a global Phase 1 trial, a Phase 1a/1b eczema trial and a Phase 2a hives trial in China, per the prospectus.

• BBT002

  Aimed at IL-4Rα and IL-5, for COPD (a long-term lung disease), chronic sinus inflammation with nasal polyps, and asthma. In a global Phase 1 trial, Phase 1/2a and Phase 2a trials in China, and a global Phase 2a asthma trial.

• BBT003

  Aimed at TL1A and IL-23p19, for inflammatory bowel disease (Crohn's disease and ulcerative colitis). Preclinical, so not yet tested in people. The company said on Oct 29, 2026 that it plans to enter the clinic by the end of 2026.

• BBT004

  Designed to remove B cells, for autoimmune diseases driven by autoantibodies. Preclinical. Bambusa has given BioNTech Zhuhai an option notice for it, per the prospectus.

• No paying customers

  Not disclosed

  Bambusa has no approved products and has reported no revenue since its inception on Mar 14, 2024. Revenue was $0 in FY2025 and in the six months to Jun 30, 2026.

• Preferred stock investors (not customers)

  Not disclosed

  Four rounds from June 2024 to January 2026 raised $136.1 million before costs. Series A-1 was about $88.9 million of that.

• IPO buyers (not customers)

  Not disclosed

  The offering raised $168.9 million before costs at $16.00 a share, priced Oct 29, 2026.

1. 1Bambusa sold nothing in FY2025: revenue was $0, because it has no approved products.
2. 2Other income, net, brought in $5.2 million, mostly a research incentive ($3.3 million) and interest ($2.2 million).
3. 3Research and development cost $38.1 million. Outside costs were $15.5 million for BBT001 and $13.0 million for BBT002.
4. 4General and administrative costs were $5.9 million, taking operating expenses to $44.0 million. Income tax, at its Australian subsidiary, was $2.2 million.
5. 5Costs were $41.1 million more than the money that came in. That is the net loss. Financing, mainly preferred stock sales, brought in $120.8 million of cash in the year.

• Rights from BioNTech Zhuhai

  BBT001 and BBT002 came from BioNTech Zhuhai, a BioNTech subsidiary then known as Biotheus, and BBT003 is licensed from it. If BioNTech Zhuhai ends the assignment agreement, the rights to BBT001 and BBT002 go back free of charge.

• Outside manufacturers

  Bambusa has no factories of its own. WuXi Biologics is the sole manufacturer of BBT001, BBT002 and BBT003, and BioNTech Zhuhai of BBT004.

• Money from investors

  $71.5 million of cash and marketable securities at Jun 30, 2026, before the IPO. Operating cash outflow was $39.8 million in FY2025.

• People

  30 full-time employees at Sep 30, 2026, 24 of them in research and development, and about 250 square feet of Boston office space.

• Dupixent (Regeneron and Sanofi)

  Approved for many of the same diseases. Global sales were $17.8 billion in 2025, per the prospectus.

• Nemluvio (Galderma)

  Named for atopic dermatitis. Global sales were $452 million in 2025, per the prospectus.

• Rinvoq (AbbVie)

  Named for atopic dermatitis and inflammatory bowel disease.

• Ebglyss (Lilly)

  Named for atopic dermatitis.

• Adbry (LEO) and Cibinqo (Pfizer)

  Named for atopic dermatitis.

• Xolair, Nucala and Tezspire

  Named for respiratory diseases; Xolair is also named for hives.

• Humira, Skyrizi, Stelara and Entyvio

  Among the drugs named for inflammatory bowel disease, the target of BBT003.

• BBT001 in eczema and hives

  Early

  The prospectus dated Oct 29, 2026 puts its initial target market at more than $35 billion by 2030

  The company says in its prospectus dated Oct 29, 2026 that it expects 12-week eczema results in two patient groups and 14-week hives results in the first half of 2027.

  Status: Early, too early to judge.

• BBT002 in lung and sinus disease

  Early

  The company estimates respiratory biologics at more than $60 billion in 2030, in its prospectus dated Oct 29, 2026

  The company says in its prospectus dated Oct 29, 2026 that it expects 4-week COPD and 12-week nasal polyp results in the first half of 2027. It also says it plans Phase 2b start-up work in 2027.

  Status: Early, too early to judge.

• BBT003 in bowel disease

  New

  The company estimates inflammatory bowel disease approaching $39 billion by 2030, in its prospectus dated Oct 29, 2026

  Preclinical. The company says in its prospectus dated Oct 29, 2026 that it plans to enter the clinic by the end of 2026.

  Status: New, recently announced.

• BBT004 in autoimmune disease

  New

  Right to nominate targets under the BioNTech Zhuhai option agreement runs through Apr 12, 2027

  Preclinical. Bambusa has given BioNTech Zhuhai an option notice, per the prospectus.

  Status: New, recently announced.

Status compares progress with what the company itself said it would do: Working = on track against what the company said; Mixed = partly on track; Behind = behind the company's own plan; New = recently announced; Early = too early to judge.

EBITDA here = operating income plus depreciation and amortization (from the cash flow statement). Fiscal years are the company's own (December 31). Net profit is the share belonging to the company's owners. Total net income differs from net profit to the company's owners: Total net loss was $41.1 million in FY2025. The $39.3 million attributable to common stockholders covers Feb 12 to Dec 31, 2025 only, because no common stock was outstanding for accounting purposes before Feb 12, 2025. EPS uses that figure. For the 2024 period the prospectus shows the attributable figure as N/A, so the net profit line shows the $13.7 million total.

Bambusa says in its 424B4 that it is an emerging growth company, so the filing gives two audited years instead of three.

Learn: Stock-based compensation and dilution: pay that becomes shares

• These figures are from before the IPO. With the offering's net proceeds and the preferred stock conversion, the prospectus shows pro forma cash and marketable securities of $223.9 million, and stockholders' equity of $217.7 million.
• Net worth is a stockholders' deficit of $71.0 million because $136.2 million of convertible preferred stock sat outside equity. That stock converted to common stock in the IPO, per the prospectus.
• Preliminary and unaudited: management estimates about $57.2 million of cash, cash equivalents and marketable securities at Sep 30, 2026. The auditor has not audited or reviewed it.
• Accumulated deficit was $77.2 million at Jun 30, 2026.
• Net cash of $71.5 million is a Cityfort calculation from 424B4 filed Oct 30, 2026: cash and marketable securities, with no debt line on the balance sheet.

Officers and directors (as a group), shares

43.5%

From the prospectus table of principal stockholders. Holdings fall after the IPO when new shares are sold; the prospectus also shows the holding after the offering.

• Shanshan Xu

  Co-founder, Chief Executive Officer, President and Chairperson

  Chair since September 2026. 2025 total pay was $1,156,022.

• Jonathan I. Lieber

  Chief Financial Officer · since 2026

  CFO since September 2026. Also part-time CFO of Rallybio.

• Thang Ho

  Co-founder, Chief Development Officer

  2025 total pay was $824,540.

• Crystal MacKay

  Chief Operating Officer

  Listed by the prospectus as a key employee.

• Helmut Jeggle

  Co-founder and director

  Linked to Salvia Investment, a holder of 22.0% before the offering.

• Howard Liang

  Lead independent director

• Derek DiRocco

  Director

  A partner at RA Capital, per its Form 4 (what this means)Form 4A filing an insider must make within two business days of buying or selling the company's shares. Learn more.

• Christian Foerster

  Director

Auditor

PwC (Boston), since 2026

Auditor changes

None in the period covered

Audit qualifications

FY2025: The auditor's report includes a going-concern paragraph.

Related-party dealings

Founders hold shares through MiNeng (Shanshan Xu) and Salvia (Helmut Jeggle). Directors' affiliates and 5% holders bought preferred stock, per the prospectus.

Credit rating

No public credit rating found

• BBT001 and BBT002: Bambusa pays a $50,000 yearly fee per program, and owes up to about $1.8 million in development and up to $11.0 million in commercial milestones per program. It had paid about $4.8 million by Jun 30, 2026.
• BBT003: a license from BioNTech Zhuhai signed Sep 28, 2025, with $1.0 million upfront. Milestones run up to $6.9 million for development, $57.5 million for first commercial sale and $217.5 million for sales, plus a low-single-digit royalty.
• Adimab, whose intellectual property is used for BBT003, was paid $0.5 million in 2025, with further milestones per product and a low-single-digit royalty.
• Salvia is linked to director Helmut Jeggle, and MiNeng to CEO Shanshan Xu. RA Capital, a partner of which sits on the board, reported buying 2,500,000 shares at $16.00 on Nov 2, 2026.

Cases are listed as the offer document describes them. A pending case is an allegation until a court or regulator decides it.

• Execution

  No approved products, and no revenue

  The prospectus says the business depends entirely on drug candidates still in development. Bambusa had a net loss of $22.4 million in the six months to Jun 30, 2026, and may never be profitable.

  Watch Trial results and any regulatory filings in later reports.

• Cash and liquidity

  Going-concern doubt and more capital needed

  Management concluded there is substantial doubt on cash before the offering. The company says in its prospectus dated Oct 29, 2026 that the offering money and existing cash last into late 2028. It says that will not carry all candidates through approval.

  Watch Cash and marketable securities in each quarterly report, against about $57.2 million (preliminary) at Sep 30, 2026.

• Competition

  Competition from approved drugs

  Dupixent, with global sales of $17.8 billion in 2025, is approved for many of the same diseases, per the prospectus. Other drugs are named for each target disease.

  Watch New approvals and trial results named in later filings.

• Regulation

  Reliance on suppliers linked to China

  WuXi Biologics, BioNTech Zhuhai and Tigermed are the China exposure the prospectus names. It flags the BIOSECURE Act, signed as Section 851 of the 2026 defense authorization act.

  Watch Any change of manufacturer, or any listing under the act, in later filings.

• Concentration

  Sole-source manufacturing

  One manufacturer makes three of its 4 candidates, and another makes the fourth. The prospectus says Bambusa relies on third-party manufacturers, many of them sole source.

  Watch Any second manufacturer named in later filings.

• Legal

  Rights can go back, and no patents are issued

  If BioNTech Zhuhai ends the assignment agreement, rights to BBT001 and BBT002 go back free of charge. All 12 patent families (7 owned, 5 in-licensed) were pending at Oct 9, 2026.

  Watch Patent grants and changes to the BioNTech Zhuhai agreements.

• Technology

  Early data may change

  The prospectus warns that interim and topline data may change as more patient data arrive. The BBT001 eczema substudy had 17 adults, and its eczema-score measures were exploratory endpoints.

  Watch The 12-week eczema results. The company says in its prospectus dated Oct 29, 2026 that it expects them in the first half of 2027.

• Immediate dilution

  Buyers at the Oct 29, 2026 offering price of $16.00 face dilution of $11.73 per share, the gap to pro forma as adjusted net tangible book value of $4.27, per the prospectus.

• Shares unlocked after 180 days

  Holders can sell remaining shares from 181 days after Oct 29, 2026, and 32,568,026 of them are held by affiliates. Registration rights cover up to 39,750,360 shares, about 98.4% of stock before the offering.

• Insiders keep a large stake

  Officers, directors and 5% holders together keep about 64.3% after the offering, per the prospectus, which leaves out purchases in the offering.

• Part of the money has no stated amount

  The prospectus states amounts for BBT001 and BBT002 only. The remainder covers earlier research, equipment and general costs, and may include licenses or acquisitions.

• No dividends

  Bambusa has never paid a dividend and says it does not intend to.

What does Bambusa Therapeutics do?

Bambusa Therapeutics (Nasdaq: BBTX), a Boston company incorporated in March 2024, is developing long-acting bispecific antibody drugs for immune and inflammatory diseases. It had no approved products as of its prospectus dated Oct 29, 2026.

How does Bambusa Therapeutics make money?

Bambusa Therapeutics does not make money yet. It reported $0 of revenue in FY2025 and in the six months to Jun 30, 2026, so it has no revenue by segment. Its business model so far is raising money from share sales and spending it on drug trials.

Is Bambusa Therapeutics profitable?

No. Bambusa Therapeutics' net loss was $41.1 million in FY2025 and $22.4 million in the six months to Jun 30, 2026, per its prospectus. Its operating loss in FY2025 was $44.0 million.

Who are Bambusa Therapeutics' customers?

Bambusa Therapeutics has no paying customers. It had no approved products as of its prospectus dated Oct 29, 2026, and has reported no revenue since its inception on Mar 14, 2024.

How big is Bambusa Therapeutics?

Bambusa Therapeutics had 30 full-time employees at Sep 30, 2026, and total assets of $77.5 million at Jun 30, 2026. It spent $38.1 million on research and development in FY2025.

What is Bambusa's BBT001?

BBT001 is Bambusa Therapeutics' lead drug candidate, an antibody aimed at IL-4Rα and IL-31, in trials for atopic dermatitis and chronic spontaneous urticaria. It is not approved. Bambusa's outside research costs for it were $15.5 million in FY2025.

What is Bambusa's BBT002?

BBT002 is a Bambusa Therapeutics drug candidate, an antibody aimed at IL-4Rα and IL-5, in trials for COPD, nasal polyps and asthma. It is not approved. Bambusa's outside research costs for it were $13.0 million in FY2025.

Who owns Bambusa Therapeutics?

Before Bambusa Therapeutics' IPO, as of Oct 23, 2026, Salvia Investment held 22.0%, CEO Shanshan Xu 21.2% and RA Capital 11.1%, per the prospectus. The 7 directors and executive officers as a group held 43.5%, a count that includes Salvia and Xu.

What is the Bambusa Therapeutics IPO?

Bambusa Therapeutics sold 10,555,555 new shares at $16.00 each under a prospectus dated Oct 29, 2026, raising $168.9 million before costs for the company. The shares first traded on Nasdaq as BBTX on Oct 30, 2026.

Numbers come only from tier 1 and tier 2 sources. Read how we research.